DRUG DISCOVERY PIPELINE
Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, nontuberculosis mycobacteria, malaria, dengue, leishmania, bacterial infections, COVID-19 and RSV, spanning over early-stage discovery to late-stage clinical trials. Click here for FNDR's areas of research focus, our publications and information about our research programs.
FNDR performs various preclinical in vitro and animal studies for BSL-2 and BSL-3 bacterial, fungal and viral pathogens under a fee-for-service mode to test therapeutics, vaccines, and other items. Click here for more information.
Drug in Clinical Development
Ongoing Innovation Projects on Infectious Disease Drug Discovery and Platform Technologies.
Repurposed drugs under development
Contract Research Projects Completed
New Drugs in Preclinical Development
Research and Development Partners
Positive results from Phase 2A clinical trial of TBA-7371, a new drug candidate for tuberculosis
29 November 2023
Foundation for Neglected Disease Research (FNDR) is proud to announce that its partners, Bill & Melinda Gates Medical Research Institute and TB Alliance, have successfully completed the Phase 2A Early Bactericidal Activity clinical trial of TBA-7371, a novel DprE1 inhibitor for the treatment of tuberculosis. The results were presented at the 2023 Union World Conference on Lung Health in Paris. TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB.